IO Biotech Inc

NASDAQ IOBT

Data sourced from

and

Daily

Download Data

IO Biotech Inc Market Capitalization on June 03, 2024: USD 80.37 M

IO Biotech Inc Market Capitalization is USD 80.37 M on June 03, 2024, a 6.20% change year over year. Market capitalization is a financial metric that represents the total value of a publicly traded company. It is calculated by multiplying the current share price of a company by the total number of outstanding shares. Market capitalization is used to assess the size and relative value of a company in the stock market. It provides investors with an idea of the company's overall worth and is often used as a basis for comparing companies within the same industry or sector. A higher market capitalization generally indicates a larger, more established company.

IO Biotech Inc 52-week high Market Capitalization is USD 133.74 M on August 16, 2023, which is 66.39% above the current Market Capitalization.
IO Biotech Inc 52-week low Market Capitalization is USD 104.09 K on May 09, 2024, which is -99.87% below the current Market Capitalization.
IO Biotech Inc average Market Capitalization for the last 52 weeks is USD 98.21 M.

NASDAQ: IOBT

IO Biotech Inc

CEO	Dr. Mai-Britt Zocca Ph.D.
IPO Date	Nov. 5, 2021
Location	Denmark
Headquarters	Ole Maaløes Vej 3, Copenhagen, Denmark, 2200
Employees	68
Sector	Healthcare
Industry	Biotechnology

Description

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

Key trends